Risk factors of advanced fibrosis in non-alcoholic fatty liver disease, associated with type 2 diabetes mellitus
https://doi.org/10.31146/1682-8658-ecg-240-8-5-12
Abstract
Aim of the investigation. To study the risk factors of advanced fibrosis in non-alcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus in relation to the vitamin D content in the blood. Materials and methods. 171 patients with NAFLD and type 2 diabetes mellitus (140 women, 31 men), aged from 31 to 69 years, were examined. Serum vitamin D levels were determined by enzyme-linked immunosorbent assay. The severity of liver fibrosis was assessed using transient elastometry. Results. In patients with NAFLD associated with type 2 diabetes mellitus liver fibrosis F3-4 was detected in 14.1% of cases and was associated with parameters of waist circumference ≥ 118 cm, platelets ≤ 225x109/l, total cholesterol ≥ 7.92 mmol/l, triglycerides ≥ 2.5 mmol/L, gammaglutamyltranspeptidase (GGT) ≥ 37 un/l, alkaline phosphatase ≥ 64 u/l, direct bilirubin ≤ 1.3 mmol/l, vitamin D ≤ 13.0 ng/ml, as well as the presence of hypertriglyceridemia. According to multivariate regression analysis, independent predictors of liver fibrosis F3-4 were blood levels of GGT, triglycerides, platelets, and vitamin D. The combination of these parameters in predicting of advanced fibrosis/cirrhosis had a sensitivity of 70.8% and a specificity of 95.6%. Conclusion. Thus, blood levels of triglycerides, platelets, and vitamin D, as well as GGT activity, were associated with fibrosis F3-4 in patients with NAFLD and type 2 diabetes mellitus, that, probably, is connected with their involvement in liver damage, inflammation, and fibrogenesis.
About the Authors
P. V. Koroy
Stavropol State Medical University
Russian Federation
Russian Federation
A. V. Yagoda
Stavropol State Medical University
Russian Federation
Russian Federation
E. O. Demurcheva
Regional Endocrinological Dispensary
Russian Federation
Russian Federation
T. R. Dudov
Stavropol State Medical University
Russian Federation
Russian Federation
References
1. European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity et al. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary. Diabetologia. 2024; 67 (11): 2375-2392. doi: 10.1007/s00125-024-06258-6.
2. Wong V.-S., Ekstedt M., Wong G.-H. et al. Changing epidemiology, global trends and implications for outcomes of NAFLD. J. Hepatol. 2023; 79 (3): 842-852. doi: 10.1016/j.jhep.2023.04.036.
3. Castera L., Cusi K. Diabetes and cirrhosis: current concepts on diagnosis and management. Hepatology. 2023; 77 (6): 2128-2146. doi: 10.1097/HEP.0000000000000263.
4. Demir M., Deyneli O., Yılmaz Y. Screening for hepatic fibrosis and steatosis in Turkish patients with type 2 diabetes mellitus: a transient elastography study. Turk. J. Gastroenterol. 2019; 30: 266-270. doi: 10.5152/tjg.2018.18559.
5. Diaconu C. T., Guja C. Nonalcoholic fatty liver disease and its complex relation with type 2 diabetes mellitus-from prevalence to diagnostic approach and treatment strategies. J. Clin. Med. 2022; 11 (17): 5144. doi: 10.3390/jcm11175144.
6. Ajmera V., Cepin S., Tesfai K. et al. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. J. Hepatol. 2023; 78 (3): 471-478. doi: 10.1016/j.jhep.2022.11.010.
7. Castera L., Laouenan C., Vallet-Pichard A. et al. High prevalence of NASH and advanced fibrosis in type 2 diabetes: a prospective study of 330 outpatients undergoing liver biopsies for elevated ALT, using a low threshold. Diabetes. Care. 2023; 46 (7): 1354-1362. doi: 10.2337/dc22-2048.
8. Luukkonen P. K., Qadri S., Ahlholm N. et al. Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease. J. Hepatol. 2022; 76 (3): 526-535. doi: 10.1016/j.jhep.2021.10.013.
9. Hatano Y., VanWagner L. B., Carnethon M. R. et al. Racial difference in the association between non-alcoholic fatty liver disease and incident type 2 diabetes: findings from the CARDIA study. Diabetologia. 2023; 66 (7): 1235-1246. doi: 10.1007/s00125-023-05903-w.
10. Oh J., Riek A. E., Bauerle K. T. et al. Embryonic vitamin D deficiency programs hematopoietic stem cells to induce type 2 diabetes. Nat.Commun. 2023; 14 (1): 3278. doi: 10.1038/s41467-023-38849-z.
11. Taderegew M. M., Woldeamanuel G. G., Wondie A. et al. Vitamin D deficiency and its associated factors among patients with type 2 diabetes mellitus: a systematic review and meta-analysis. BMJ Open. 2023; 13: e075607. doi: 10.1136/bmjopen-2023-075607.
12. Chen X., Wan Z., Geng T. et al. Vitamin D status, vitamin D receptor polymorphisms, and risk of microvascular complications among individuals with type 2 diabetes: a prospective study. Diabetes. Care. 2023; 46 (2): 270-277. doi: 10.2337/dc22-0513.
13. Yuan S., Larsson S. C. Inverse association between serum 25-hydroxyvitamin D and nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 2023; 21: 398-405. doi: 10.1016/j.cgh.2022.01.021.
14. Saberi B., Dadabhai A. S., Nanavati J. et al. Vitamin D levels do not predict the stage of hepatic fibrosis in patients with non-alcoholic fatty liver disease: a PRISMA compliant systematic review and meta-analysis of pooled data. World J. Hepatol. 2018; 10 (1): 142-154. doi: 10.4254/wjh.v10.i1.142.
15. Poustchi H., Alaei-Shahmiri F., Aghili R. et al. Hepatic steatosis and fibrosis in type 2 diabetes: a risk-based approach to targeted screening. Arch. Iran. Med. 2021; 24 (3): 177-186. doi: 10.34172/aim.2021.28.
16. Chen K., Sng W. K., Quah J. H.-M. et al. Clinical spectrum of non-alcoholic fatty liver disease in patients with diabetes mellitus. PLoS One. 2020; 15 (8): e0236977. doi: 10.1371/journal.pone.0236977.
17. Alfadda A. A., Sherbeeni S. M., Alqutub A. N. et al. Transient elastography for the prevalence of non-alcoholic fatty liver disease in patients with type 2 diabetes. Saudi. J. Gastroenterol. 2022; 28: 426-433. doi: 10.4103/sjg.sjg_73_22.
18. Tuong T. T.K., Tran D. K., Phu P. Q.T. et al. Non-alcoholic fatty liver disease in patients with type 2 diabetes: evaluation of hepatic fibrosis and steatosis using Fibroscan. Diagnostics. 2020; 10: 159. doi: 10.3390/diagnostics10030159.
19. Yu H., Su X., Tao W. et al. Prevalence and characteristics of liver steatosis and fibrosis in type 2 diabetes mellitus (T2DM) patients: a cross-sectional study in populations of eastern China. BMJ Open. 2024; 14: e087550. doi: 10.1136/bmjopen-2024-087550.
20. Ciardullo S., Monti T., Perseghin G. High prevalence of advanced liver fibrosis assessed by transient elastography among U.S. adults with type 2 diabetes. Diabetes Care. 2021; 44 (2): 519-525. doi: 10.2337/dc20-1778.
21. Younossi Z. M., Golabi P., de Avila L. et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J. Hepatol. 2019; 71 (4): 793-801. doi: 10.1016/j.jhep.2019.06.021.
22. Huang N., Su X., Yu T. et al. Serum 25-hydroxy vitamin D level is associated with elastography-detected liver fibrosis in patients with type 2 diabetes mellitus in China. Front. Endocrinol. 2024; 15: 1420088. doi: 10.3389/fendo.2024.1420088.
23. Ciardullo S., Muraca E., Cannistraci R. et al. Low 25 (OH) vitamin D levels are associated with increased prevalence of nonalcoholic fatty liver disease and significant liver fibrosis. Diabetes Metab. Res. Rev. 2023; 39 (5): e3628. doi: 10.1002/dmrr.3628.
24. Xing Y., Cheng T., Zhou F., Ma H. The association between vitamin D and type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease: an observational cross-sectional study. Diabetes Metab. Syndr. Obes. 2022; 15: 269-280. doi: 10.2147/DMSO.S348870.
25. Zhang Y., Li J., Ni Y. et al. Correlational study on the levels of 25-hydroxyvitamin D and non-alcoholic fatty liver disease in type 2 diabetic patients. BMC Endocrine Disorders. 2021; 21: 100. doi: 10.1186/s12902-021-00762-1.
26. Fang J.-X., Han Y., Meng J. et al. Relationship between non-alcoholic fatty liver and progressive fibrosis and serum 25-hydroxy vitamin D in patients with type 2 diabetes mellitus. BMC Endocrine Disorders. 2024; 24: 108. doi: 10.1186/s12902-024-01640-2.
27. Cai J., Zhang Z., Liu J. et al. Correlation between serum 25-OH vitamin D expression and non-alcoholic fatty liver disease. Exp. Ther. Med. 2020; 19 (3): 1681-1686. doi: 10.3892/etm.2020.8411
28. Stefan N., Schick F., Birkenfeld A. L. et al. The role of hepatokines in NAFLD. Cell. Metab. 2023; 35 (2): 236-252. doi: 10.1016/j.cmet.2023.01.006.
29. Li Y., Qin M., Zhong W. et al. RAGE promotes dysregulation of iron and lipid metabolism in alcoholic liver disease. Redox. Biol. 2023; 59: 102559. doi: 10.1016/j.redox.2022.102559.
30. Gong L., Wei F., Gonzalez F. J. et al. Hepatic fibrosis: targeting peroxisome proliferator-activated receptor alpha from mechanism to medicines. Hepatology. 2023; 78 (5): 1625-1653. doi: 10.1097/HEP.0000000000000182.
31. Du T., Xiang L., Zhang J. et al. Vitamin D improves hepatic steatosis in NAFLD via regulation of fatty acid uptake and b-oxidation. Front Endocrinol. 2023; 14 (8): 1138078. doi: 10.3389/fendo.2023.1138078.
32. Yagoda A. V., Koroy P. V., Slyadnev S. A. positive correlation of the level of molecules of superfamily immunoglobulins icam-1, vcam-1 and pecam-1 with the index of fibrosis in nonalcoholic fatty liver disease. Experimental and Clinical Gastroenterology. 2017; (2):45-51. (In Russ.)@@ Ягода А. В., Корой П. В., Сляднев С. А. Положительная корреляция уровня молекул суперсемейства иммуноглобулинов ICAM-1, VCAM-1, PECAM-1 с показателями индекса фиброза при неалкогольной жировой болезни печени. Экспериментальная и клиническая гастроэнтерология. 2017; 138 (2):45-51.
33. Andrade T. G., Xavier L. C.D., Souza F. F., Araújo R. C. Risk predictors of advanced hepatic fibrosis in patients with nonalcoholic fatty liver disease - a survey in a university hospital in Brazil. Arch. Endocrinol. Metab. 2022; 66 (6): 823-830. doi: 10.20945/2359-3997000000514.
34. Balaphas A., Meyer J., Sadoul K. et al. Platelets and platelet-derived extracellular vesicles in liver physiology and disease. Hepatol.Commun. 2019; 3 (7): 855-866. doi: 10.1002/hep4.1358.
35. Zhong L.-K., Zhang G., Lu S.-Y. et al. The value of platelet count in evaluating the degree of liver fibrosis in patients with chronic hepatitis B. J. Clin. Lab. Anal. 2020; 34 (7): e23270. doi: 10.1002/jcla.23270.
36. Mussbacher M., Brunnthaler L., Panhuber A. et al. Till death do us part - the multifaceted role of platelets in liver diseases.Int. J. Mol. Sci. 2021; 22: 3113. doi: 10.3390/ijms22063113.
37. Lu W., Li X., Liu N. et al. Vitamin D alleviates liver fibrosis by inhibiting histidine-rich calcium binding protein (HRC). Chem. Biol.Interact. 2021; 334: 109355. doi: 10.1016/j.cbi.2020.109355.
38. Roth C. L., Elfers C. T., Figlewicz D. P. et al. Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and toll-like receptor activation. Hepatology. 2012; 55 (4): 1103-1111. doi: 10.1002/hep.24737.
39. Kwok R. M., Torres D. M., Harrison S. A. Vitamin D and nonalcoholic fatty liver disease (NAFLD): is it more than just an association? Hepatology. 2013; 58: 1166-1174. doi: 10.1002/hep.26390.Evividissulto es C. Dium.
Review
For citations:
Koroy P.V., Yagoda A.V., Demurcheva E.O., Dudov T.R. Risk factors of advanced fibrosis in non-alcoholic fatty liver disease, associated with type 2 diabetes mellitus. Experimental and Clinical Gastroenterology. 2025;(8):5-12. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-240-8-5-12
Views:
6
JATS XML
Email this article 
